Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Myelodysplastic Syndromes 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Thrombocytosis 1Rhabdomyosarcoma 1Recurrence 1Polycythemia 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × GRN163L peptide × Clear all
NCT01256762 2016-01-26

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Geron Corporation

Phase 2 Completed
166 enrolled
Breast

Breast Neoplasms

NCT00732056 2015-12-24

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

Geron Corporation

Phase 1 Completed
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡